Novo Nordisk at BIO-Europe 2026
Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website
Novo Nordisk takes part in 4 sessions at BIO-Europe 2026 in Cologne. Its sessions centre on cardiometabolic medicine beyond GLP-1 and on longevity, along with pharma productivity. It also looks at the conditions that help biopharma partnerships succeed, and Novo Nordisk sponsors the meeting.
| Organization | BIO-Europe 2026 Attendance |
|---|---|
Novo Nordisk Bagsværd, Denmark | ◆Gold Sponsor |
Danish pharmaceutical company, branded Novo since September 2026, making medicines for diabetes, obesity and rare diseases. | Panel Mon Nov 9 11:00–11:45 Unlocking Pharma’s Productivity Potential Why developing medicines keeps getting costlier and slower, and whether AI and research sourced from other companies can make drug companies more productive. Business of Biotech Panel Tue Nov 10 15:30–15:55 Accelerating Innovation: Creating the Right Environment for Success in Biopharma Partnerships How to design partnerships that work, from payments tied to research milestones and shared risk to guarding intellectual property while sharing ideas. Panel Tue Nov 10 10:00–10:45 Cardiometabolic innovations beyond GLP-1 – Where are we now? Which drug approaches beyond GLP-1 medicines are drawing attention for obesity, diabetes and heart disease risk, and where money and partnerships are going. Panel Tue Nov 10 15:00–15:45 Longevity – Are we getting younger? What recent research shows about treatments that could slow or reverse aging, and how investment in this young field is taking shape. |
Instantly find 20 buyers from Novo Nordisk
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by EBD Group, Informa Connect or BIO-Europe. Submit a correction